Notice of Intent To Grant an Exclusive License of a U.S. Government-Owned Patent

Riepilogo

In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7 (a)(I)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license to U.S. patent number 5,607,979 issued March 4, 1997 entitled "Topical Skin Protectants" to DFB Pharmaceuticals, Inc. with its principal place of business at 3909 Hulen Street, Fort Worth, Texas 76107. The exclusive field of use will be the prevention or treatment of contact and allergic dermatitis, as well as dermatitis or wounds caused by incontinence.